Effect of Aging on Bariatric Surgery-induced Changes in Metabolism and Cognition
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02088190 |
Recruitment Status :
Recruiting
First Posted : March 14, 2014
Last Update Posted : February 24, 2021
|
Sponsor:
Ohio State University
Information provided by (Responsible Party):
David Bradley MD, Ohio State University
Tracking Information | |||||
---|---|---|---|---|---|
First Submitted Date | March 11, 2014 | ||||
First Posted Date | March 14, 2014 | ||||
Last Update Posted Date | February 24, 2021 | ||||
Study Start Date | April 2014 | ||||
Estimated Primary Completion Date | April 2022 (Final data collection date for primary outcome measure) | ||||
Current Primary Outcome Measures |
Change in Insulin Sensitivity [ Time Frame: Change from baseline in Insulin sensitivity at 15% weight loss (up to 4 months after surgery) ] Subjects will undergo a clamp procedure to assess insulin sensitivity at baseline and 15% weight loss after surgery
|
||||
Original Primary Outcome Measures | Same as current | ||||
Change History | |||||
Current Secondary Outcome Measures |
Change in Beta cell function [ Time Frame: Change from baseline to 15% weight loss (up to 4 months after surgery) ] | ||||
Original Secondary Outcome Measures | Same as current | ||||
Current Other Pre-specified Outcome Measures | Not Provided | ||||
Original Other Pre-specified Outcome Measures | Not Provided | ||||
Descriptive Information | |||||
Brief Title | Effect of Aging on Bariatric Surgery-induced Changes in Metabolism and Cognition | ||||
Official Title | Effect of Aging on Bariatric Surgery-induced Changes in Metabolism and Cognition | ||||
Brief Summary | The investigators hypothesize that the improvements in insulin sensitivity, beta (β)-cell function, and inflammation will be greater, and the improvement in sarcopenic obesity will be less, in younger versus older individuals after substantial weight loss induced by sleeve gastrectomy bariatric surgery. | ||||
Detailed Description | With an aging population that is increasingly susceptible to obesity and obesity-related comorbidities including sarcopenia and diabetes, effective and safe treatment options tailored to the needs of older adults are imperative. While medication and lifestyle interventions generally fail to achieve sustained large-scale weight loss, bariatric surgery is the most effective long-term weight loss treatment for obese patients and improves many of the medical complications associated with obesity. Sleeve gastrectomy (SG) results in substantial weight loss and may be more appropriate for older adults due to its low rate of complications and mortality. Therefore, SG has been proposed as a reasonable primary treatment modality in older obese individuals, with a substantial recent increase in the number of interventions performed. Despite the potential benefits, very little is known of the physiologic and metabolic effects of bariatric surgery, including SG, on glucose homeostasis and muscle physiology in older adults. A fundamental understanding of the effects of excess adiposity and weight loss interventions is of profound importance, especially with emerging evidence that earlier treatment of obesity may delay/prevent many comorbidities. An underlying inflammatory state has been implicated in the pathogenesis of sarcopenia and insulin resistance and may provide an important connection to the age-related declines seen in older obese patients. Therefore, this study aims to evaluate the modifying effect of age and inflammation on the SG-induced changes in body composition, muscle physiology, and insulin sensitivity. This protocol will be conducted in two age cohorts (greater than 60 and less than 50 years old). | ||||
Study Type | Observational | ||||
Study Design | Observational Model: Cohort Time Perspective: Prospective |
||||
Target Follow-Up Duration | Not Provided | ||||
Biospecimen | Not Provided | ||||
Sampling Method | Probability Sample | ||||
Study Population | Patients scheduled to undergo laparoscopic sleeve gastrectomy (SG) at The Ohio State University (OSU) Wexner Medical Center will be divided into two cohorts: 1). Greater than or equal to 60 years of age and 2). Less than 60 years of age. | ||||
Condition |
|
||||
Intervention | Procedure: Sleeve gastrectomy
Type of bariatric surgery
|
||||
Study Groups/Cohorts |
|
||||
Publications * | Not Provided | ||||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
|||||
Recruitment Information | |||||
Recruitment Status | Recruiting | ||||
Estimated Enrollment |
22 | ||||
Original Estimated Enrollment | Same as current | ||||
Estimated Study Completion Date | April 2022 | ||||
Estimated Primary Completion Date | April 2022 (Final data collection date for primary outcome measure) | ||||
Eligibility Criteria | Inclusion Criteria:
Exclusion Criteria:
|
||||
Sex/Gender |
|
||||
Ages | 21 Years to 80 Years (Adult, Older Adult) | ||||
Accepts Healthy Volunteers | Yes | ||||
Contacts |
|
||||
Listed Location Countries | United States | ||||
Removed Location Countries | |||||
Administrative Information | |||||
NCT Number | NCT02088190 | ||||
Other Study ID Numbers | ENDO-235 | ||||
Has Data Monitoring Committee | Yes | ||||
U.S. FDA-regulated Product | Not Provided | ||||
IPD Sharing Statement |
|
||||
Responsible Party | David Bradley MD, Ohio State University | ||||
Study Sponsor | Ohio State University | ||||
Collaborators | Not Provided | ||||
Investigators |
|
||||
PRS Account | Ohio State University | ||||
Verification Date | February 2021 |